UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | C000000356 |
|---|---|
| Receipt number | R000000453 |
| Scientific Title | Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia |
| Date of disclosure of the study information | 2006/03/20 |
| Last modified on | 2012/09/12 13:05:30 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia
Acronym
HSCT for aplastic anemia using alemtuzumab
Scientific Title
Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia
Scientific Title:Acronym
HSCT for aplastic anemia using alemtuzumab
Region
| Japan |
Condition
Condition
Aplastic anemia
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To determine the appropriate dose of alemtuzumab for aplastic anemia in allogeneic HSCT and to investigate whether HSCT using such dose of alemtuzumab can be safely performed.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase I,II
Assessment
Primary outcomes
Survival on day 60 after transplantation
Engraftment within 60 days
Incidence of grade II to IV acute GVHD within 60 days
Key secondary outcomes
• Regimen-related toxicity
• Incidence of infectious disease
• Overall survival at day 365
• Therapeutic efficacy for aplastic anemia
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Alemtuzumab is added to the fludarabine-based regimen at 0.16 – 0.25 mg/kg per day for 6 days (days -10 to -5).
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Patients with transfusion-dependent moderately severe, severe or very severe acquired aplastic anemia persisting for 6 months or longer after immunosuppressant treatment with ATG alone or in combination with cyclospoline.
(2) Patients who have an HLA-matched or 1-locus-mismatched related donor or an HLA-matched unrelated donor.
(3) ECOG performance status of 0 or 1.
(4) Good major organ functions.
Key exclusion criteria
(1) Diabetes uncontrollable even with regular insulin use.
(2) Uncontrollable hypertension.
(3) Current active infection.
(4) 5% or more malignant cell involvement in bone marrow.
(5) Abnormality in chromosome 7 detected by bone marrow G-banding or FISH.
(6) Current active cancer.
(7) Pregnant or nursing women or women who may be pregnant.
(8) Uncontrollable mental illness.
(9) Hepatitis B virus antigen-positive (HBsAg or HBeAg).
(10) HIV-positive.
(11) A history of hypersensitivity to transplant conditioning agents (fludarabine phosphate, cyclophosphamide) or agents for GVHD prophylaxis (ciclosporin, methotrexate).
(12) A history of hematopoietic stem cell transplantation.
Target sample size
38
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shuichi Taniguchi |
Organization
Federation of National Public Service Personnel Mutual Aid Association
Toranomon Hospital
Division name
Department of Hematology
Zip code
Address
2-2-2 Toranomon, Minato-ku,
TEL
03-3588-1111
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yoshinobu Kanda |
Organization
The University of Tokyo Hospital
Division name
Department of Hematology & Oncology
Zip code
Address
7-3-1 Hongo,Bunkyo-ku, Tokyo
TEL
03-3815-5411
Homepage URL
ycanda-tky@umin.ac.jp
Sponsor or person
Institute
GCP-ISS HE0403 group
Institute
Department
Personal name
Funding Source
Organization
2004 Health and Labor Sciences Research Grant (Research on Measures for Intractable Diseases) of the Ministry of Health, Labor and Welfare.
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2006 | Year | 03 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2004 | Year | 10 | Month | 22 | Day |
Date of IRB
Anticipated trial start date
| 2004 | Year | 12 | Month | 01 | Day |
Last follow-up date
| 2009 | Year | 07 | Month | 01 | Day |
Date of closure to data entry
| 2009 | Year | 07 | Month | 01 | Day |
Date trial data considered complete
| 2009 | Year | 11 | Month | 01 | Day |
Date analysis concluded
| 2010 | Year | 03 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2006 | Year | 03 | Month | 13 | Day |
Last modified on
| 2012 | Year | 09 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000453
